1. Home
  2. TDF vs CAPR Comparison

TDF vs CAPR Comparison

Compare TDF & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Dragon Fund Inc.

TDF

Templeton Dragon Fund Inc.

HOLD

Current Price

$11.22

Market Cap

284.8M

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$26.23

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TDF
CAPR
Founded
1994
2005
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
284.8M
324.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TDF
CAPR
Price
$11.22
$26.23
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$41.38
AVG Volume (30 Days)
79.2K
5.8M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$11,130,509.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,736.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.15
$4.30
52 Week High
$10.62
$40.37

Technical Indicators

Market Signals
Indicator
TDF
CAPR
Relative Strength Index (RSI) 47.86 70.54
Support Level $10.95 $25.60
Resistance Level $11.44 $27.18
Average True Range (ATR) 0.16 3.39
MACD -0.00 0.33
Stochastic Oscillator 51.55 59.68

Price Performance

Historical Comparison
TDF
CAPR

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: